Meeting Coverage
IASLC
International Association for the Study of Lung Cancer
Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT
Latest IASLC Meeting Coverage
Confirmed responses reached 29.8% in heavily pretreated patients
Randomized data suggest surgery increases risk of death by 28% over first 42 months
Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone
Median overall survival reached 19.3 months in Chinese trial
Long-term follow-up shows continued survival benefit as first-line treatment
Meaningful survival boosts in POSEIDON trial of front-line durvalumab, tremelimumab, and chemo
Results show need to integrate sexual health into care, researcher says
Phase II trial supports neoadjuvant nivolumab plus chemotherapy
Overall survival benefit now demonstrated
Early phase results set the stage for KRAS/immune-targeted combo as potential first-line option
Large randomized study shows non-inferiority to lobectomy
Study finds minimal improvements in the early diagnosis of young patients with lung cancer
Early trials of DZD9008 demonstrated responses in over a third of patients
More than 90% disease control rate, hint of improved PFS in pilot trial